Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.
A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.
An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.
In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.
Using 18F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.
The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.
The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.
Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.
Researchers recommend against the routine use of high-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis inpatients with melanoma after observing poorer oncologic outcomes with high versus low doses.
An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.
The magnitude of the survival benefit associated with immune checkpoint inhibitor treatment appears to be sex dependent, with women benefiting less than men, according to a meta-analysis published in The Lancet Oncology.
The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate.
Adjuvant pembrolizumab significantly improves recurrence-free survival, compared with placebo, when given to patients with high-risk stage III melanoma for up to 1 year, researchers report in The New England Journal of Medicine.
Circulating tumor DNA can differentiate pseudoprogression from true disease progression in patients with metastatic melanoma undergoing immunotherapy, a study suggests.
Receiving neoadjuvant plus adjuvant dabrafenib and trametinib significantly improves event-free survival compared with standard care in patients with high-risk melanoma, phase II study findings indicate.
Adding immune checkpoint inhibitors to targeted therapy or radiotherapy can worsen some of the toxic effects associated with these treatment modalities, indicate two reports published in JAMA Oncology.
Patients with metastatic melanoma who achieve a complete response with pembrolizumab therapy have a low risk for disease progression or death, report researchers who believe that treatment discontinuation is possible in this setting.